Search

Your search keyword '"Cheson, B. D."' showing total 377 results
Start Over Author "Cheson, B. D."
377 results on '"Cheson, B. D."'

7. CALGB 50801 (ALLIANCE): PET ADAPTED THERAPY IN BULKY STAGE I/II CLASSIC HODGKIN LYMPHOMA (CHL)

Author

LaCasce, A. S., primary, Dockter, T., additional, Ruppert, A., additional, Kostakoglu, L., additional, Schöder, H., additional, Hsi, E. D., additional, Bogart, J. A., additional, Cheson, B. D., additional, Wagner‐Johnston, N. D., additional, Abramson, J. S., additional, Maddocks, K. J., additional, Leonard, J. P., additional, and Bartlett, N. L., additional

Published
2021
Full Text
View/download PDF

15. Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma.

Author

Ujjani, C., Wang, H., Broome, C., Gopal, A., Lai, C., Warren, E., Shadman, M., Smith, S. D., Lynch, R., Swanson, N., Grossfeld, T., Sorensen, T., Cheson, B. D., and Dunleavy, K.

Subjects
FOLLICULAR lymphoma, VENETOCLAX, COVID-19 pandemic
Abstract

Pts received a median of 1 prior therapy (range 1-8). B Background: b Ibrutinib (I) and venetoclax (V) have modest single-agent activity in relapsed/refractory follicular lymphoma (FL) (Gopal A, JCO 2018; Davids M, JCO 2017). Grade 3/4 adverse events (AE) included neutropenia (NTP) (21%), febrile NTP (14%), diarrhea (21%), nausea (14%), hypertension (14%), thrombocytopenia (7%), atrial fibrillation (7%), vomiting (7%), ALT/AST elevation (7%), COVID pneumonia (7%). [Extracted from the article]

Published
2023
Full Text
View/download PDF

16. PATTERNS OF IDELALISIB TREATMENT-EMERGENT LYMPHOCYTOSIS IN PATIENTS WITH CLL OR SLL

Author

Ghia, P., Cheson, B. D., Furman, R. R., Hallek, M., Hillmen, P., O'Brien, S. M., Sharman, J. P., Dubowy, R. L., Velasco, B., Waldapfel, C. C., Zelenetz, A. D., Brown, J. R., Ghia, P., Cheson, B. D., Furman, R. R., Hallek, M., Hillmen, P., O'Brien, S. M., Sharman, J. P., Dubowy, R. L., Velasco, B., Waldapfel, C. C., Zelenetz, A. D., and Brown, J. R.

Published
2016

17. EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Author

Stilgenbauer, S., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Hallek, M. J., Coiffier, B., O'Brien, S. M., Tausch, E., Kreuzer, K. A., Jiang, W., Jahn, T. M., Lazarov, M., Sharman, J. P., Stilgenbauer, S., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Hallek, M. J., Coiffier, B., O'Brien, S. M., Tausch, E., Kreuzer, K. A., Jiang, W., Jahn, T. M., Lazarov, M., and Sharman, J. P.

Published
2014

18. EFFECT OF IDELALISIB/RITUXIMAB COMBINATION TREATMENT OF RELAPSED CLL ON THE BCR SIGNALING-RELATED CHEMOKINES CCL3 AND CCL4: DATA FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Author

Ghia, P., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Hallek, M. J., Coiffier, B., O'Brien, S. M., Stilgenbauer, S., Jiang, W., Jahn, T. M., Wong, M., Lazarov, M., Sharman, J. P., Ghia, P., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Hallek, M. J., Coiffier, B., O'Brien, S. M., Stilgenbauer, S., Jiang, W., Jahn, T. M., Wong, M., Lazarov, M., and Sharman, J. P.

Published
2014

19. HEALTH-RELATED QUALITY OF LIFE IMPACT OF IDELALISIB (IDELA) IN PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PHASE 3 RESULTS

Author

Eradat, H. A., Ghia, P., O'Brien, S. M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Cheson, B. D., Pagel, J. M., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Lamanna, N., Hallek, M. J., Coiffier, B., Pettitt, A., Kim, Y., Jahn, T. M., Wagner, L. I., Eradat, H. A., Ghia, P., O'Brien, S. M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Cheson, B. D., Pagel, J. M., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Lamanna, N., Hallek, M. J., Coiffier, B., Pettitt, A., Kim, Y., Jahn, T. M., and Wagner, L. I.

Published
2014

20. Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL

Author

Hallek, M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Pagel, J. M., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H., Erwin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., O'Brien, S. M., Cheson, B. D., Ruppert, S., Kroenig, H., Schuster, A., Hallek, M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Pagel, J. M., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H., Erwin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., O'Brien, S. M., Cheson, B. D., Ruppert, S., Kroenig, H., and Schuster, A.

Published
2014

21. SECOND INTERIM ANALYSIS OF A PHASE 3 STUDY EVALUATING IDELALISIB AND RITUXIMAB FOR RELAPSED CLL

Author

Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H. A., Lamanna, N., Coiffier, B., Pettitt, A., Li, X., Jahn, T. M., O'Brien, S. M., Hallek, M. J., Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H. A., Lamanna, N., Coiffier, B., Pettitt, A., Li, X., Jahn, T. M., O'Brien, S. M., and Hallek, M. J.

Published
2014

22. 2nd analysis of a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib and Rituximab for previously treated patients with chronic lymphocytic leukemia

Author

Hallek, M., Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I, Ghia, P., Eradat, H., Erwin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., O'Brien, S. M., Ruppert, S., Schuster, A., Kroenig, H., Hallek, M., Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I, Ghia, P., Eradat, H., Erwin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., O'Brien, S. M., Ruppert, S., Schuster, A., and Kroenig, H.

Published
2014

24. Report of an international working group to standardize response criteria for myelodysplastic syndromes

Author

Cheson, B. D., Bennett, J. M., Kantarjian, H., Pinto, A., Schiffer, C. A., Nimer, S. D., Lowenberg, B., Beran, M., Witte, T. M., Stone, R. M., Mittelman, M., GUILLERMO SANZ, Wijermans, P. W., Gore, S., Greenberg, P. L., and Hematology

Subjects
Experimental diagnostics and therapy of malignancies, Hematopoiesis and stem cell transplantation
Abstract

Item does not contain fulltext

Published
2000

27. Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized U.S. Intergroup Trial E2496.

Author

Evens, A. M., primary, Hong, F., additional, Gordon, L. I., additional, Fisher, R. I., additional, Bartlett, N., additional, Connors, J. M., additional, Wagner, H., additional, Gospodarowicz, M. K., additional, Cheson, B. D., additional, Advani, R., additional, Kahl, B. S., additional, Hoppe, R. T., additional, and Horning, S. J., additional

Published
2011
Full Text
View/download PDF

41. High expression of nucleoside transporter hENT1 predicts a worse event-free survival in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine, and liposomal doxorubicin—A CALGB 59804 correlative study

Author

Lai, R., primary, Hsi, E. D., additional, Mackey, J., additional, Jung, S., additional, Johnson, J. L., additional, Cook, J. R., additional, Jones, D., additional, Said, J. W., additional, Cheson, B. D., additional, and Bartlett, N. L., additional

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results